Agendia Highlights Study Showing MammaPrint/BluePrint Tests Predict Response to Current Breast Cancer Chemotherapy and Targeted Therapy Regimens

Researchers Present Data at Breast Cancer Symposium Showing MammaPrint/BluePrint Can Identify Women Who Benefit from Chemotherapy and Targeted Dual Anti-HER2 Drug Treatment Before Surgery IRVINE, CA and AMSTERDAM, THE NETHERLANDS – Agendia’s MammaPrint® and BluePrint® tests provide new insights that may provide many … Continued

DNA repair deficiency biomarkers identify HR+/HER2- breast cancer patients who may benefit from veliparib/carboplatin: results from the I-SPY 2 TRIAL

Author(s): L. van 't Veer, L. Esserman, A. Sanil, A. Glas, T. Severson, S. Linn, L. Brown-Swigart, G. Hirst, I-SPY 2 TRIAL Investigators, O. Olapade, H .Rugo, D. Berry, D. M. Wolf, and C. Yau

Background In I-SPY 2, HER2- patients were adaptively randomized to receive standard chemotherapy or the PARP inhibitor veliparib with carboplatin (V/C) and chemotherapy. V/C graduated in the triple-negative (TN) subtype, and we have previously shown that DNA repair deficiency signatures [PARPi-7 and BRCAness] … Continued

High concordance of protein (by IHC), gene (by FISH; HER2 only), and microarray readout (by TargetPrint) of ER, PgR, and HER2: results from the EORTC 10041/BIG 03-04 MINDACT trial.

Publication Name: Annals of Oncology

Author(s): Viale G, Slaets L, Bogaerts J, Rutgers E, van't Veer L, Piccart-Gebhart MJ, de Snoo FA, Stork-Sloots L, Russo L, Dell'Orto P, van den Akker J, Glas A, Cardoso F; TRANSBIG Consortium & the MINDACT Investigators.

BACKGROUND: To investigate the correlation of TargetPrint with local and central immunohistochemistry/fluorescence in situ hybridization assessment of estrogen (ER), progesterone (PgR), and human epidermal growth factor receptor 2 (HER2) in the first 800 patients enrolled in the MINDACT trial. PATIENTS … Continued

Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature

Publication Name: British Journal of Cancer

Author(s): M Knauer, F Cardoso, J Wesseling, PL Bedard, SC Linn, EJT Rutgers, and LJ van 't Veer

BACKGROUND: Overexpression of HER-2 is observed in 15–25% of breast cancers, and is associated with increased risk of recurrence. Current guidelines recommend trastuzumab and chemotherapy for most HER-2-positive patients. However, the majority of patients does not recur and might thus … Continued

Microarray-Based Determination of Estrogen Receptor, Progesterone Receptor, and HER2 Receptor Status in Breast Cancer

Publication Name: Clinical Cancer Research

Author(s): Paul Roepman, Hugo M. Horlings, Oscar Krijgsman, Marleen Kok, Jolien M. Bueno-de-Mesquita, Richard Bender, Sabine C. Linn, Annuska M. Glas and Marc J. van de Vijver

Purpose: The level of estrogen receptor (ER), progesterone receptor (PR), and HER2 aids in the determination of prognosis and treatment of breast cancer. Immunohistochemistry is currently the predominant method for assessment, but differences in methods and interpretation can substantially affect … Continued